Medications Used to Treat Systemic Lupus Erythematosus
Robert Katz, MD
Chairman of the Board, Lupus Society of Illinois
Professor of Medicine, Rush University
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can affect multiple organs and systems, including the skin, joints, blood cells, and kidneys. Treatment focuses on controlling inflammation, preventing disease flares, protecting organ function, and minimizing long-term damage. Because lupus affects each person differently, treatment plans must be individualized based on disease activity, the organs involved, and the patient’s response to therapy.
Biologic Medications
Biologic medications have become important treatment options for people with active lupus. Benlysta (belimumab) and Saphnelo (anifrolumab) are biologic therapies approved for specific manifestations of SLE. Benlysta is also approved to treat active lupus nephritis, a form of lupus that affects the kidneys. Saphnelo is used to treat moderate-to-severe nonrenal SLE and is not specifically approved for lupus nephritis.
These medications target specific components of the immune system involved in lupus, offering additional options for patients whose disease remains active despite conventional treatment.
Additional Treatments for Lupus Nephritis
Lupus nephritis can cause inflammation and damage to the kidneys and may require more intensive treatment. Gazyva (obinutuzumab) is approved for adults with active lupus nephritis, while Lupkynis (voclosporin) is used in combination with standard immunosuppressive therapy to treat active lupus nephritis.
These treatments expand the options available to patients and may help control kidney inflammation and preserve kidney function when used as part of an individualized treatment plan.
Traditional Medications
Traditional medications continue to play a central role in lupus management. Hydroxychloroquine (Plaquenil) is recommended for most people with lupus unless it is contraindicated. It can help control disease activity and reduce the risk of flares.
Immunosuppressive medications, including azathioprine (Imuran) and mycophenolate mofetil (CellCept), are used to manage selected manifestations of lupus, depending on disease severity and the organs affected.
Prednisone and other corticosteroids can quickly reduce inflammation and help control active disease. However, long-term corticosteroid use can cause significant side effects. Treatment strategies therefore generally aim to use the lowest effective dose for the shortest appropriate duration while maintaining disease control.
Rituximab for Difficult-to-Treat Lupus
Rituximab (Rituxan) is a biologic medication that targets B cells, a type of immune cell involved in antibody production and autoimmune activity. Although rituximab is not specifically FDA-approved for SLE, physicians may use it off-label in selected patients with severe or treatment-resistant disease.
Emerging Therapies: CAR T-Cell Treatment
For patients with exceptionally difficult-to-treat lupus, CAR T-cell therapy is an emerging area of research. This approach modifies a patient’s T cells so they can target specific immune cells involved in disease activity.
Early clinical studies have generated interest in the possibility of achieving prolonged remission in some people with severe autoimmune diseases, including lupus. However, CAR T-cell therapy remains investigational for lupus and is not yet an established treatment. Further research is needed to understand its long-term effectiveness, safety, and potential role in lupus care.
Other cellular therapies are also being investigated. For example, obecabtagene autoleucel is a CAR T-cell therapy developed primarily for certain B-cell malignancies. It should not be considered an established treatment for lupus nephritis, and any potential role in lupus would need to be supported by specific clinical-trial evidence.
Looking Ahead
The range of treatments available for lupus continues to expand, offering hope for more personalized approaches to care. From established medications to newer biologic therapies and investigational treatments, each option has potential benefits and risks that must be considered carefully.
Treatment decisions should be made in partnership with a qualified healthcare professional and tailored to the patient’s disease activity, organ involvement, previous treatment response, and risk of side effects. The ultimate goal is to achieve sustained disease control, prevent flares, preserve organ function, and minimize irreversible damage while supporting the best possible quality of life.
This article is intended for educational purposes only and is not a substitute for professional medical advice. Patients should consult their healthcare providers before making changes to their treatment.
